Finance

Lists
SWOBY:OTCMKTS
Swedish Orphan Biovitrum ADR
$24.29
0.00%
(0.00) 1D
Sep 2, 3:02:39 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SWOBY...
Mkt. cap
162.55B
Avg. vol.
67.00
Volume
55.00
52-wk high
$29.32
52-wk low
$14.84
Beta
265.66
Shares outstanding
714.83M
No. of employees
2K
Mkt. cap
162.55B
Avg. vol.
67.00
Volume
55.00
52-wk high
$29.32
52-wk low
$14.84
Beta
265.66
Shares outstanding
714.83M
No. of employees
2K
Profile
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA. Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. In 2025 it had a revenue of SEK 28.2 billion and around 1,900 employees. Wikipedia
About Swedish Orphan Biovitrum ADR
CEOGuido Oelkers
Employees2.12K
Founded1939
Headquarters-
SectorBiotechnology
Websitesobi.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.78B
7.82B
7.18B
7.84B
Cost of goods sold
1.56B
1.51B
1.70B
1.83B
Cost of revenue
1.56B
1.51B
1.70B
1.83B
Research and development expenses
754.00M
879.00M
948.00M
1.13B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.63B
2.93B
2.62B
2.89B
Operating expense
3.41B
3.75B
3.57B
4.03B
Total operating expenses
4.97B
5.26B
5.27B
5.86B
Operating income
2.80B
2.56B
1.91B
1.98B
Other non operating income
1.00M
-25.00M
1.00M
1.00M
EBT including unusual items
-4.03B
2.17B
1.68B
1.41B
EBT excluding unusual items
2.64B
2.32B
1.72B
1.77B
Income tax expense
-1.13B
310.00M
363.00M
315.00M
Effective tax rate
28.12%
14.27%
21.59%
22.29%
Other operating expenses
26.00M
-57.00M
1.00M
8.00M
Net income
-2.89B
1.86B
1.32B
1.10B
Net profit margin
-37.22%
23.81%
18.35%
13.99%
Earnings per share
6.05
5.65
4.07
3.96
Interest and investment income
-
22.00M
-
-
Interest expense
-168.00M
-156.00M
-173.00M
-204.00M
Net interest expenses
-168.00M
-134.00M
-173.00M
-204.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.71B
3.13B
2.69B
2.78B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps